Fig 1. Immunization with Ad35.HSV.gD2 induces HSV-2 specific humoral immune responses in BALB/c mice.

Female BALB/c mice were immunized intramuscularly once (T = 0d) or twice (T = 0d and T = 28d) with 10⁸ to 10¹⁰ vp/mouse Ad35.HSV.gD2 (N = 5/group), twice with 7x10⁵ pfu/mouse CJ2-gD2 (N = 5) (T = 0d and T = 28d) or mock immunized with formulation buffer (N = 5) and sacrificed 6 weeks after the first immunization. Serum samples were collected (T = 42d) and analyzed for (a) HSV-2 Virus Neutralizing antibody titers (shown as log₂ IC₅₀) and (b) gD2 IgG ELISA titers (shown as log10 EU/ml). (c) Cross-reactive neutralizing antibody titers against HSV-1 KOS virus (shown as log₂ IC₅₀) and (d) gD1 IgG ELISA titers (shown as log₁₀ endpoint titers) were only measured in sera from mice receiving 2-dose regimens. Dotted lines indicate the lower limit of quantification (LLoQ, gD2 ELISA) or limit of detection (LOD, other assays) and horizontal lines indicate the mean value per group. (a-b) (Across dose) statistical comparison and (c-d) highest dose comparison was performed by ANOVA with Bonferroni correction. Results of statistical analysis are depicted by asterisks: *p<0.05, ** p<0.01, *** p<0.001; ns: not significant.